KIA
VNDA icon

Kopp Investment Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Kopp Investment Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,285
Closed -$156K – 67
2017
Q4 		$156K Sell
10,285
-1,735
-14% -$25.7K 0.16% 64
2017
Q3 		$215K Hold
12,020
– – 0.2% 61
2017
Q2 		$196K Buy
+12,020
New +$173K 0.18% 61

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Kopp Investment Advisors's VNDA Position: Q1 2018 in Review

Kopp Investment Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q1 2018, closing a stake of 10,285 shares — an estimated $156K sold.

Kopp Investment Advisors first reported a position in VNDA in Q2 2017 and held it in 3 quarters. The position peaked at $215K in Q3 2017. 131 funds tracked by Wall St. Rank hold VNDA as of Q1 2018.

  • Kopp Investment Advisors reported no remaining Vanda Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Kopp Investment Advisors sold 10,285 Vanda Pharmaceuticals shares in Q1 2018, an estimated $156K.
  • Kopp Investment Advisors first reported a position in Vanda Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Kopp Investment Advisors's Vanda Pharmaceuticals position peaked at $215K in Q3 2017.
  • 131 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2018.

Based on Kopp Investment Advisors's 13F filing for Q1 2018, filed 14 May 2018.